References
- 1
Siersema P D.
Photodynamic therapy for Barrett"s esophagus: not yet ready for the premier league
of endoscopic interventions.
Gastrointestinal Endoscopy.
2005;
62
503-507
- 2
Wilson B C, Patterson M S, Wilson B C, Patterson M S.
The physics, biophysics and technology of photodynamic therapy.
Phys Med Biol.
2008;
53
61-R109
- 3
Birkmeyer J D, Stukel T A, Siewers A E. et al .
Surgeon volume and operative mortality in the United States.
N Engl J Med.
2003;
349
2117-2127
- 4
Lightdale C J, Heier S K, Marcon N E. et al .
Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG
laser for palliation of esophageal cancer: a multicenter randomized trial.
Gastrointest Endosc.
1995;
42
507-512
- 5 Dougherty T. Photodynamic therapy for early esophageal cancer [abstract]. International
Photodynamic Therapy Association Meeting 1990.
- 6
Laukka M A, Wang K K.
Initial results using low-dose photodynamic therapy in the treatment of Barrett’s
esophagus.
Gastrointest Endosc.
1995;
42
59-63
- 7
Overholt B F, Panjehpour M.
Barrett’s esophagus: photodynamic therapy for ablation of dysplasia, reduction of
specialized mucosa, and treatment of superficial esophageal cancer.
Gastrointest Endosc.
1995;
42
64-70
- 8
Overholt B F, Lightdale C J, Wang K K. et al .
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in
Barrett’s esophagus: international, partially blinded, randomized phase III trial.
[Erratum appears in Gastrointest Endosc 2006; 63 : 359].
Gastrointest Endosc.
2005;
62
488-498
- 9
Overholt B F, Wang K K, Burdick J S. et al .
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s
high-grade dysplasia.
Gastrointest Endosc.
2007;
66
460-468
- 10
Pech O, Gossner L, May A. et al .
Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial
Barrett’s cancer and high-grade intraepithelial neoplasia.
Gastrointest Endosc.
2005;
62
24-30
- 11
Hage M, Siersema P D, van Dekken H. et al .
5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation
of Barrett’s oesophagus: a randomised trial.
Gut.
2004;
53
785-790
- 12
Peters F, Kara M, Rosmolen W. et al .
Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade
dysplasia and early cancer in Barrett esophagus after endoscopic resection.
Endoscopy.
2005;
37
418-424
- 13
Mackenzie G D, Jamieson N F, Novelli M R. et al .
How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic
acid for ablation of high-grade dysplasia in Barrett’s esophagus.
Lasers in Med Sci.
2008;
23
203-210
- 14
Hur C, Nishioka N S, Gazelle G S.
Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with
high grade dysplasia.
Dig Dis Sci.
2003;
48
1273-1283
- 15
Shaheen N J, Inadomi J M, Overholt B F, Sharma P.
What is the best management strategy for high grade dysplasia in Barrett’s oesophagus?
A cost effectiveness analysis.
Gut.
2004;
53
1736-1744
- 16
Comay D, Blackhouse G, Goeree R. et al .
Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness
analysis.
Can J Gastroenterol.
2007;
21
217-222
- 17
Comay D, Blackhouse G, Goeree R. et al .
Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness
analysis.
Can J Gastroenterol.
2007;
21
217-222
- 18
Prasad G A, Wang K K, Buttar N S. et al .
Predictors of stricture formation after photodynamic therapy for high-grade dysplasia
in Barrett’s esophagus.
Gastrointest Endosc.
2007;
65
60-66
- 19
Prasad G A, Wang K K, Buttar N S. et al .
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia
in Barrett’s esophagus.
Gastroenterology.
2007;
132
1226-1233
- 20
Sharma V K, Wang K K, Overholt B F. et al .
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus:
1-year follow-up of 100 patients.
Gastrointest Endosc.
2007;
65
185-195
- 21
Mörk H, Barth T, Kreipe H H. et al .
Reconstitution of squamous epithelium in Barrett’s oesophagus with endoscopic argon
plasma coagulation: a prospective study.
Scand J Gastroenterol.
1998;
33
1130-1134
- 22
Van Laethem J L, Cremer M, Peny M O. et al .
Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression:
immediate and mid term results.
Gut.
1998;
43
747-751
- 23
Cheung R, Solonenko M, Busch T M. et al .
Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced
depth of necrosis in a murine tumor model.
J Biomed Optics.
2003;
8
248-252
- 24
Solonenko M.
In vivo reflectance measurement of optical properties, blood oxygenation and motexafin
lutetium uptake in canine large bowels, kidneys and prostates.
Phys Med Biol.
2002;
47
857-873
- 25
Sessler J L, Miller R A.
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic
therapy.
Biochem Pharmacol.
2000;
59
733-739
- 26
Vargas A, Eid M, Fanchaouy M. et al .
In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation
properties, administration parameters and biological issues involved in PDT outcome.
Eur J Pharm Biopharm.
2008;
69
43-53
- 27
Saw C L, Heng P W, Olivo M. et al .
Potentiation of the photodynamic action of hypericin.
J Environ Pathol Toxicol Oncol.
2008;
27
23-33
- 28
Minnes R, Weitman H, You Y. et al .
Dithiaporphyrin derivatives as photosensitizers in membranes and cells.
J Phys Chem B.
2008;
112
3268-3276
- 29
Cole C D, Liu J K, Sheng X. et al .
Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in
a GH4C1 rat tumor model.
J Neurooncol.
2008;
87
255-261
- 30
Trachtenberg J, Bogaards A, Weersink R A. et al .
Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer
for recurrent prostate cancer following definitive radiation therapy: assessment of
safety and treatment response.
J Urol.
2007;
178
1974-1979; discussion 1979
- 31
Taquet J P, Frochot C, Manneville V. et al .
Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy.
Curr Med Chem.
2007;
14
1673-1687
- 32
Prasad G A, Wang K K, Halling K C. et al .
Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus.
Gastroenterology.
2008;
135
370-379
K. WangMD
Gastroenterology E19B
Rochester
MN 55905
USA
Fax: +1-507-2557612
Email: wang.kenneth@mayo.edu
